CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $2.48B, above the global median of $1.15B
- FinancialsAltman Z-Score 0.5: distress zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.48BUSDvs all stocks (USD)
Revenue (TTM)
1.29BUSDvs all stocks (USD)
Profit Margin
-7.79%Beta
1.64xvs all stocks
52-Week Change
151.34%vs all stocks
Market Capitalization
2.48BUSDvs all stocks (USD)
Enterprise Value
3.49BUSDvs all stocks (USD)
Forward P/E
-14.48xPrice to Sales (TTM)
1.92xPrice to Book (MRQ)
2.97xEnterprise to Revenue
2.72xEnterprise to EBITDA
16.44xGross Margin
48.51%Profit Margin
-7.79%Operating Margin
0.23%Return on Assets (TTM)
0.36%Return on Equity (TTM)
-8.74%Revenue (TTM)
1.29BUSDvs all stocks (USD)
Revenue per Share (TTM)
5.01USDUpdated Jul 18, 2026Quarterly Revenue Growth
5.70%Gross Profit (TTM)
632.75MUSDvs all stocks (USD)
EBITDA (TTM)
238.76MUSDvs all stocks (USD)
Net Income (TTM)
-113.21MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
4.59%Operating Cash Flow (TTM)
120.27MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
82.49MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
83.93MUSDFY2025 · Dec 31, 2025Revenue
1.27BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
637.11MUSDFY2025 · Dec 31, 2025Gross Profit
631.02MUSDFY2025 · Dec 31, 2025Operating Income
25.45MUSDvs all stocks (USD)
Pre-tax Income
-78.21MUSDFY2025 · Dec 31, 2025Income Tax Expense
123.69MUSDFY2025 · Dec 31, 2025Net Income
-270.45MUSDFY2025 · Dec 31, 2025EBIT
22.61MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
245.76MUSDFY2025 · Dec 31, 2025Research & Development
805.00KUSDFY2025 · Dec 31, 2025Selling, General & Administrative
458.07MUSDFY2025 · Dec 31, 2025Other Operating Expenses
5.30MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
663.00KUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
100.83MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.3500USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.3500USDFY2025 · Dec 31, 2025Basic Shares Outstanding
762.09MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
762.09MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-201.90MUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
-2.92MUSDFY2025 · Dec 31, 2025Operating Cash Flow
3.31MUSDFY2025 · Dec 31, 2025Free Cash Flow
-59.44MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
101.57MUSDFY2025 · Dec 31, 2025Income Tax Paid
27.06MUSDFY2025 · Dec 31, 2025Interest Paid
103.61MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-201.90MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
216.04MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-34.09MUSDFY2025 · Dec 31, 2025Stock-based Compensation
35.74MUSDFY2025 · Dec 31, 2025Other Non-cash Items
6.24MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
6.70MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-5.20MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-20.22MUSDFY2025 · Dec 31, 2025Capital Expenditures
-62.75MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-1.21MUSDFY2025 · Dec 31, 2025Net Acquisitions
-542.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-173.00KUSDFY2025 · Dec 31, 2025Other Investing Activity
-4.75MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-68.21MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
83.19MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-117.36MUSDFY2025 · Dec 31, 2025Other Financing Charges
-39.58MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-73.75MUSDFY2025 · Dec 31, 2025Shares Outstanding
260.49MSharesUpdated Jul 18, 2026Float Shares
225.97MSharesUpdated Jul 18, 2026% Held by Insiders
25.80%vs all stocks
% Held by Institutions
7.57%vs all stocks
Total Cash (MRQ)
106.13MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.4020USDUpdated Jul 18, 2026Total Debt (MRQ)
1.04BUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
1.15xCurrent Ratio (MRQ)
1.56xBook Value per Share (MRQ)
3.15USDUpdated Jul 18, 2026Total Assets
2.85BUSDvs all stocks (USD)
Total Current Assets
448.62MUSDFY2025 · Dec 31, 2025Total Liabilities
2.01BUSDFY2025 · Dec 31, 2025Total Non-current Assets
2.40BUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
1.71BUSDFY2025 · Dec 31, 2025Total Current Liabilities
294.31MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
89.17MUSDFY2025 · Dec 31, 2025Accounts Receivable
73.86MUSDFY2025 · Dec 31, 2025Inventory
225.02MUSDFY2025 · Dec 31, 2025Accounts Payable
74.72MUSDFY2025 · Dec 31, 2025Short-term Debt
67.25MUSDFY2025 · Dec 31, 2025Deferred Revenue
3.60MUSDFY2025 · Dec 31, 2025Other Current Liabilities
19.93MUSDFY2025 · Dec 31, 2025Long-term Debt
759.71MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
207.50MUSDFY2025 · Dec 31, 2025Common Stock (Book)
0.00USDFY2025 · Dec 31, 2025Retained Earnings
-1.59BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
840.28MUSDvs all stocks (USD)
52-Week Low
2.92USDUpdated Jul 18, 202652-Week High
15.15USDUpdated Jul 18, 202652-Week Change
151.34%vs all stocks
Beta
1.64xvs all stocks
50-Day MA
10.32USDUpdated Jul 18, 2026200-Day MA
8.52USDUpdated Jul 18, 2026Avg 10-Day Volume
137.34KSharesUpdated Jul 18, 2026Avg 30-Day Volume
241.02KSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-0.4200USDUpdated Jul 18, 2026Other Income / Expense
-3.50MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Within or Near the Altman Distress Zone
Debt is a large share of its assets, and large against its cash flow.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.49Profit Margin: -0.08
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 1.56Altman Z-Score: 0.50
Financial Health
Altman Z-Score 0.5: distress zoneCritical
Altman Z-Score: 0.50
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $2.48B, above the global median of $1.15BNotable
Market cap (USD): 2,483,801,480Global Median: 1,146,734,693.424
Revenue is $1.29B, above the global median of $520.53MNotable
Revenue (USD): 1,285,741,952Global Median: 520,528,949.311
Levered free cash flow is $82.49M, above the global median of $16.24MNotable
Levered free cash flow (USD): 82,494,752Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
ApicHope Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Regencell Bioscience Holdings Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tonghua Dongbao Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
China Resources Double Crane Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
HUTCHMED
Tier 1ProductionApproval-Gated PipelineRule
Pharvaris N.V.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Immunome Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Shandong Buchang Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
GN Store Nord A/S
Tier 1ProductionApproval-Gated PipelineRuleFlow
TransMedics Group Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule